Teva Bids $125M for BioXcel’s IGALMI in Bankruptcy Sale

Teva Pharmaceuticals International GmbH has entered a court-supervised auction as stalking horse bidder for IGALMI, BioXcel Therapeutics' dexmedetomidine sublingual film, a novel drug delivery format currently under FDA review for at-home acute treatment of agitation in adults with schizophrenia or bipolar I or II disorder. The bid signals how distressed-asset proceedings under Section 363 of Chapter 11 of the U.S. Bankruptcy Code are increasingly functioning as a structured pipeline acquisition channel for specialty pharma operators.

The proposed transaction carries an upfront payment of $57.5 million, with up to $67.5 million in contingent payments tied to FDA approval timing and specified sales milestones. Teva would acquire worldwide rights to the dexmedetomidine sublingual film assets; the agreement does not encompass BioXcel Therapeutics as a corporate entity. If Teva is outbid at auction, it retains entitlement to a break-up fee and expense reimbursement under the agreement terms.

For manufacturing and regulatory leads, the asset's profile warrants close attention. Dexmedetomidine sublingual film is a proprietary orally dissolving film formulation, a delivery format that carries distinct process validation and stability considerations relative to conventional oral solid dose. Any technology transfer to Teva's network would require alignment with 21 CFR Part 211 manufacturing controls and ICH Q10 pharmaceutical quality system requirements, particularly given the product's pending regulatory status and the compressed timelines that contingent, approval-linked payments can create.

The clinical unmet need framing is operationally relevant: if FDA approves the product for outpatient use, it would represent the first at-home treatment option for acute agitation in this population, shifting the dispensing and pharmacovigilance model away from institutional settings. QA and regulatory affairs teams at Teva would need to account for that distribution profile in their post-approval commitments and risk management planning.

Bankruptcy court approval, the outcome of the competitive auction, and FDA clearance each represent independent gating conditions before the asset can enter Teva's commercial portfolio, making the $67.5 million in contingent payments a direct proxy for the regulatory and commercial risk Teva is pricing into the deal structure.

Source: GlobeNewswire via BioXcel Therapeutics / Teva Pharmaceutical Industries Ltd. press release, 28 August 2026.